Abstract |
An open-label, non-comparative study assessed the clinical and bacteriological efficacy of gemifloxacin (320 mg, once-daily for 7 days) in lower respiratory tract infections (LRTI). Patients with acute exacerbation of chronic bronchitis (AECB, n=261) or community-acquired pneumonia (CAP, n=216) were enrolled into the study. Clinical success rates at follow-up (days 21-28) in the intent-to-treat (ITT) population were high, 83.1% in AECB patients (95% CI: 77.9, 87.4) and 82.9% in CAP patients (95% CI: 77.0, 87.5). High bacteriological success rates were achieved (bacteriological ITT population), 91.2% (52/57) in AECB patients (95% CI: 80.0, 96.7) and 77.9% (60/77) in CAP patients (95% CI: 66.8, 86.3). Gemifloxacin was well tolerated with a low incidence of adverse events. Gemifloxacin treatment resulted in high clinical and bacteriological success rates and is a well-tolerated therapy for the treatment of LRTIs.
|
Authors | P Ball, T M File, M Twynholm, T Henkel |
Journal | International journal of antimicrobial agents
(Int J Antimicrob Agents)
Vol. 18
Issue 1
Pg. 19-27
(Jul 2001)
ISSN: 0924-8579 [Print] Netherlands |
PMID | 11463522
(Publication Type: Clinical Trial, Clinical Trial, Phase III, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Infective Agents
- Fluoroquinolones
- Naphthyridines
- Gemifloxacin
|
Topics |
- Adult
- Aged
- Anti-Infective Agents
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Bronchitis
(drug therapy, microbiology)
- Chronic Disease
- Community-Acquired Infections
(drug therapy, microbiology)
- Drug Administration Schedule
- Female
- Fluoroquinolones
- Gemifloxacin
- Gram-Negative Bacterial Infections
(drug therapy, microbiology)
- Haemophilus Infections
(drug therapy, microbiology)
- Humans
- Klebsiella Infections
(drug therapy, microbiology)
- Male
- Middle Aged
- Naphthyridines
(administration & dosage, adverse effects, pharmacology, therapeutic use)
- Pneumococcal Infections
(drug therapy, microbiology)
- Pneumonia, Bacterial
(drug therapy, microbiology)
- Staphylococcal Infections
(drug therapy, microbiology)
- Treatment Failure
|